Technology ID
TAB-4869

Advancing Anthrax Detection with Monoclonal Antibodies Against Bacillus anthracis Protective Antigen

E-Numbers
E-048-2018-0
Lead Inventor
Leppla, Stephen
Lead IC
NIAID
ICs
NIAID
Applications
Medical Devices
Diagnostics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Research Products
Antibodies

This technology involves the creation of monoclonal antibodies through hybridoma technology, specifically, hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12, which exhibit a high degree of reactivity with Bacillus anthracis protective antigen (PA). These monoclonal antibodies have shown great promise in the field of anthrax detection and diagnosis. Their exceptional specificity for Bacillus anthracis PA suggests their potential application in diagnostic devices. The utilization of these antibodies by organizations like InBios has the potential to significantly enhance the accuracy and speed of anthrax detection, a critical advancement in the realms of public health and biodefense. Further research and development efforts may unlock the full potential of these antibodies for practical diagnostic solutions.

 

Commercial Applications
The monoclonal antibodies produced by hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12 offer promising applications in the field of anthrax detection, enabling the development of rapid and highly accurate diagnostic tests for Bacillus anthracis infections. These antibodies have the potential to enhance public health efforts by facilitating swift and precise identification of anthrax cases, thus improving patient outcomes. Additionally, they can play a crucial role in biodefense and biosafety measures, aiding in the detection of Bacillus anthracis in various settings and contributing to the safeguarding of public health and national security.

Competitive Advantages
The monoclonal antibodies produced by hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12 offer a significant competitive advantage in anthrax detection. Their exceptional specificity for Bacillus anthracis protective antigen (PA) ensures highly accurate and reliable diagnosis, reducing the likelihood of false results. This precision and reliability make them a valuable asset for organizations in the field of public health and biodefense seeking to develop advanced anthrax detection methods.
Licensing Contact: